Teriparatide (PTH 1-34)

At a glance

Standard Protocol

Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (PTH1 Receptor); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation.

• Hypercalcemia: the most pharmacologically expected adverse effect; teriparatide transiently elevates serum calcium through bone resorption activation and renal reabsorption; symptoms include nausea, weakness, constipation, confusion, and cardiac arrhythmia at severe levels; occurs most commonly in the first months; serum calcium should be monitored 1 month after initiation.
• Hypercalciuria: elevated urinary calcium excretion parallel to hypercalcemia; important to monitor in subjects with a history of nephrolithiasis.
• Nausea: one of the most commonly reported adverse effects in clinical trials; onset often within 1-2 hours of injection; related to the acute PTH pulse.
• Dizziness and orthostatic hypotension: particularly in the hour following injection; injecting while sitting or lying down reduces risk.
• Leg cramps: most frequent musculoskeletal adverse effect in clinical trials; lower extremity muscle cramping within hours of dosing.
• Headache: commonly reported in clinical trial data; transient.
• Joint aches and arthralgia: reported in a subset of subjects; related to calcium flux and bone remodeling activity.
• Fatigue: general; particularly in early treatment weeks as the PTH signaling establishes new bone remodeling dynamics.
• Injection site reactions: pain, redness, swelling, and bruising at the subcutaneous injection site; typically mild and self-limiting.
• Elevated serum uric acid: reported in clinical trials; mechanism not fully characterized; may be relevant in subjects with gout or hyperuricemia.
• Osteosarcoma (theoretical in humans): carries a black box FDA warning based on rat carcinogenicity studies at supraphysiologic lifetime doses; no confirmed osteosarcoma cases attributed to teriparatide have been documented in human clinical use across over two decades of post-marketing surveillance.
• Elevated alkaline phosphatase: expected pharmacological response to osteoblast activation; not an adverse event per se but a monitored laboratory marker.
• Tachycardia: transient; related to acute PTH pulse and calcium flux; reported in some subjects within minutes of injection.

• Paget's disease of bone: the abnormal, accelerated bone turnover that characterizes Paget's disease creates unpredictable and potentially excessive osteoblast responses to PTH1R stimulation; absolute contraindication.
• Prior radiation therapy to the skeleton: radiotherapy permanently alters bone cell biology and increases the theoretical risk of radiation-induced sarcoma development in cells stimulated by PTH1R activation; absolute contraindication per FDA label.
• Open growth plates in pediatric subjects: teriparatide stimulates osteoblast proliferation at endosteal and periosteal surfaces; in subjects with active growth plates, uncontrolled stimulation of growth plate osteoprogenitor cells carries developmental and theoretical sarcoma risk.
• Unexplained elevated serum alkaline phosphatase: high ALP indicates abnormal bone turnover that may reflect undiagnosed Paget's, malignancy, or other bone disease; requires investigation before teriparatide initiation.
• History of primary malignancy with skeletal metastases or high risk of skeletal metastasis: PTH1R stimulation in bone with metastatic lesions may accelerate lesion growth; contraindicated.
• Pre-existing hypercalcemia: teriparatide increases serum calcium via both increased bone resorption (transient) and increased renal calcium reabsorption; in subjects already hypercalcemic, further calcium elevation risks cardiac arrhythmia, nephrocalcinosis, and soft tissue calcification.
• Primary hyperparathyroidism: endogenous PTH is already elevated; the mechanism mimics the continuous PTH exposure that drives bone resorption rather than formation.
• Severe renal impairment (CrCl < 30 mL/min): teriparatide has not been adequately studied in subjects with severe renal failure; calcium/phosphate dysregulation risk is amplified.
• Concurrent bisphosphonate therapy: bisphosphonates inhibit the osteoclast activity that PTH requires to prime osteoblast formation signaling; co-administration significantly blunts teriparatide efficacy; sequential therapy (bisphosphonate after teriparatide is discontinued) is the preferred strategy.
• Pregnancy: PTH1R signaling has roles in fetal skeletal development; safety not established; avoid.
• Breastfeeding: not recommended; safety data insufficient.
• Prior teriparatide or abaloparatide treatment completing 24-month cumulative lifetime exposure: the 24-month maximum is a lifetime cap that applies across all cycles; exceeded use carries the osteosarcoma risk on which the FDA boxed warning is based.
• Known hypersensitivity to teriparatide or any formulation excipients including metacresol (the preservative used in multidose pens).

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0
• https://pubmed.ncbi.nlm.nih.gov/?term=Teriparatide+%28PTH+1-34%29
• https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=teriparatide